美国麻醉医师协会分级作为肾细胞癌患者预后因素的应用。
The use of the American Society of Anesthesiology Classification as a prognostic factor in patients with renal cell carcinoma.
作者信息
de Cássio Zequi Stênio, de Campos Eurico C R, Guimarães Gustavo C, Bachega Wilson, da Fonseca Francisco P, Lopes Ademar
机构信息
Service of Urology, Department of Pelvic Surgery, Hospital AC Camargo, São Paulo, Brazil.
出版信息
Urol Int. 2010;84(1):67-72. doi: 10.1159/000273469. Epub 2010 Feb 17.
OBJECTIVES
We analyzed whether the American Society of Anesthesiology (ASA) classification could be used as a prognostic factor in renal cell carcinoma.
METHODS
ASA classification's impact on cancer-specific survival (CSS) and on overall survival in 145 patients submitted to radical or partial nephrectomy was evaluated, and was compared with clinicopathological variables.
RESULTS
CSS was influenced by ASA in uni- and multivariate analyses. Five-year CSS was 95.7, 71.1 and 39.8% for ASA 1, ASA 2 and ASA 3, respectively (p = 0.007). The ASA classification influenced the overall survival too (p < 0.001). When 18 patients with metastases were excluded, the CSS was 95.7, 83.9 and 42.9% for ASA 1, ASA 2 and ASA 3, respectively (p = 0.001). ASA 3 patients had ten times more metastases than ASA1 patients and two times more than ASA 2 patients (p = 0.001). ASA 3 patients had fewer incidental tumors (p = 0.043) than ASA 2 and 3 patients.
CONCLUSION
In this series, the ASA classification could be used as a prognostic factor in renal cell carcinoma.
目的
我们分析了美国麻醉医师协会（ASA）分级是否可作为肾细胞癌的预后因素。
方法
评估了ASA分级对145例行根治性或部分肾切除术患者的癌症特异性生存率（CSS）和总生存率的影响，并与临床病理变量进行比较。
结果
单因素和多因素分析中，CSS均受ASA影响。ASA 1、ASA 2和ASA 3患者的5年CSS分别为95.7%、71.1%和39.8%（p = 0.007）。ASA分级也影响总生存率（p < 0.001）。排除18例有转移的患者后，ASA 1、ASA 2和ASA 3患者的CSS分别为95.7%、83.9%和42.9%（p = 0.001）。ASA 3患者的转移灶比ASA 1患者多10倍，比ASA 2患者多2倍（p = 0.001）。ASA 3患者的偶然肿瘤比ASA 1和ASA 2患者少（p = 0.043）。
结论
在本系列研究中，ASA分级可作为肾细胞癌的预后因素。
Zotero 插件